title: Enhanced healing of full-thickness burn wounds using di-rhamnolipid.
abstract: The aim of this study was to investigate the properties of di-rhamnolipid [alpha-L-rhamnopyranosyl-(1-2)-alpha-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid, also referred to as di-rhamnolipid BAC-3] relating to the process of cutaneous wound healing. Di-rhamnolipid was prepared in a eucerin ointment and applied topically on full-thickness burn wounds in normal Sprague-Dawley rats covering 5% of the total body surface area. The rate of wound closure was measured over the period of 45 days. The collagen content was evaluated microscopically, by performing densitometric analysis on Verhoeff's stained histopathological slides of wound biopsies taken at the end of 45th day of di-rhamnolipid treatment. Di-rhamnolipid toxicity was assessed with the subcutaneous multi-dose study in Swiss-Webster mice. The treatment of full-thickness-burn wounds with topical 0.1% di-rhamnolipid accelerated the closure of wounds on day 21 of the treatment by 32% compared to the control (p < 0.05). On day 35, the wounds closed in all animals-treated with 0.1% di-rhamnolipid ointment while some rats in the control group had open wounds on days 35 and even 45. Histologic comparisons have shown that di-rhamnolipid significantly decreased collagen content in burn wounds (47.5%, p < 0.05) as compared to the vehicle-treated (control) wounds. Di-rhamnolipid was well-tolerated. The results of this study raise the possibility of potential efficacy of di-rhamnolipid in accelerating normal wound healing and perhaps in overcoming defects associated with healing failure in chronic wounds.
authors.affiliation: TajCo Inc., 2323 Shasta Drive #40, Davis, CA 95616, USA. tamara@irb.hr
authors.forename: Tamara
authors.initials: T
authors.lastname: Stipcevic
authors.forename: Ante
authors.initials: A
authors.lastname: Piljac
authors.forename: Goran
authors.initials: G
authors.lastname: Piljac
mesh_terms: D000818:Animals; D002056:Burns / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006017:Glycolipids / Q000009:adverse effects / Q000627:therapeutic use*; D007150:Immunohistochemistry; D051379:Mice; D009824:Ointments / Q000009:adverse effects / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D006017:Glycolipids; D009824:Ointments; C418382:rhamnolipid